MedTrace Logo

CA-125 in Screening Patients at High Risk for Ovarian Cancer

NCT00080639 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-08-05

No results posted yet for this study

Summary

RATIONALE: Measuring levels of CA 125 in blood samples of women who have a high risk of developing ovarian cancer may help doctors detect cancer early and plan more effective treatment.

PURPOSE: This phase II trial is studying CA-125 levels in screening for cancer in women who are at high risk of developing ovarian cancer.

Conditions

Interventions

OTHER

physiologic testing

PROCEDURE

study of high risk factors

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Edward E. Partridge, MD · University of Alabama at Birmingham

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00080639 on ClinicalTrials.gov